Supplemental figures and legends from Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies

Abstract

<p>Figure S1. Expression of tumor-associated antigens in mouse tumor cell lines; Table S1. Number of complete responses in CT26 tumor-bearing mice that were treated with EphA2-Tub or EphA2-PBD; Figure S2. Activity of EphA2-Tub and EphA2-PBD in the Renca tumor model; Fig. S3. Control IgG-ADCs are minimally active in CT26, MCA205, 4T1, and RENCA tumor models, demonstrating target specificity for EphA2-ADC; Figure S4. CD8+ T cells are important for the efficacy of ADCs in the CT26 model; Table S2. Summary of results from combining ADCs with checkpoint inhibitors or TNFR agonists; Figure S5. Blood lymphocyte count of non-tumor bearing BALB/c and C57BL/6 mice following dosing with EphA2-Tub or EphA2-PBD; Figure S6. Combination of EphA2-ADCs with anti-PD1 or PD-L1; Figure S7. Combination of EphA2-ADCs with GITRL FP or OX40L FP; Figure S8. Activity of ADCs in the MCA205 model; Figure S9. Antitumor activity studies in the Renca model; Figure S10. Normalized CD45+ cells in the Renca model; Fig. S11. Detection of EphA2 in syngeneic mouse models via immunohistochemistry; Figure S12. Immunophenotyping of myeloid cells in the Renca model</p>